Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021968 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02021968 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants.
The verdict
NCT02021968, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Dengue viruses can cause dengue illness ranging from a mild illness to life-threatening disease. The purpose of this study is to evaluate the protective effectiveness of a dengue virus vaccine in healthy adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL rDEN2∆30-7169
- BIOLOGICAL TetraVax-DV-TV003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02021968
The ClinicalTrials.gov registry entry for NCT02021968 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02021968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02021968 about?
NCT02021968 is a clinical study titled "Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults". Dengue viruses can cause dengue illness ranging from a mild illness to life-threatening disease. The purpose of this study is to evaluate the protective effectiveness of a dengue virus vaccine in healthy adults.
What is the current status of trial NCT02021968?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02021968?
The interventions under investigation include: Placebo (BIOLOGICAL), rDEN2∆30-7169 (BIOLOGICAL), TetraVax-DV-TV003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02021968?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.